{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.950","upperLimit":"4.167","value":"2.0000"},{"groupId":"OG001","lowerLimit":"0.500","upperLimit":"5.933","value":"2.1667"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3326595.","dispersionType":"Full Range","groups":[{"description":"Participants received GSK3326595 400 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG000","title":"Part 1: GSK3326595 400 mg"},{"description":"Participants received GSK3326595 300 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG001","title":"Part 1: GSK3326595 300 mg"}],"paramType":"MEDIAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Day 1:Pre-dose(within 1 hour prior to dosing),5minute(+/-2minute),30minute(+/-5minute),1hour(+/-5minute),2hours(+/-5minute),3hours(+/-5minute),4hours(+/-10minute),6hours(+/-10minute),8hours(+/-15minute),12hours(+/-2hour), 24hours(+/-2hour) post-dose","title":"Part 1: Time of Maximum Concentration Observed (Tmax) of GSK3326595 Following Administration of Single Dose","type":"SECONDARY","unitOfMeasure":"Hours"}